https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Design and synthesis of arylhydrocarbon receptor ligands for the treatment of breast cancer https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:36694 Wed 24 Jun 2020 17:13:55 AEST ]]> Postmastectomy radiation therapy in women with T1-T2 tumors and 1 to 3 positive lymph nodes: analysis of the Breast International Group 02-98 Trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:32260 Wed 16 May 2018 15:44:20 AEST ]]> Phosphorylation of calcium/calmodulin-stimulated protein kinase II at T286 enhances invasion and migration of human breast cancer cells https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:30150 Wed 13 Jan 2021 17:37:19 AEDT ]]> Prevalence of PALB2 mutations in Australian familial breast cancer cases and controls https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:27356  G variant (rs152451) was significantly enriched in cases and may represent a low-penetrance polymorphism (p = 0.002; OR 1.24 (95 % CI 1.09–1.47). Conclusions: Our findings support truncating variants in PALB2 as high-penetrance breast cancer susceptibility alleles, and suggest that a common missense variant may also lead to a low level of increased breast cancer risk.]]> Wed 11 Apr 2018 17:01:50 AEST ]]> Sortilin is associated with breast cancer aggressiveness and contributes to tumor cell adhesion and invasion https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:27772 Wed 11 Apr 2018 15:54:06 AEST ]]> Docosahexaenoic acid inhibits the invasion of MDA-MB-231 breast cancer cells through upregulation of cytokeratin-1 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:27950 in vitro invasion assays showed that siRNA against KRT1 was able to reverse the DHA-induced inhibition of breast cancer cell invasion. In conclusion, KRT1 is involved in the anti-invasive activity of DHA in breast cancer cells.]]> Wed 11 Apr 2018 15:01:51 AEST ]]> The role of short tandem repeats in genetic susceptibility to breast and endometrial cancers https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:23272 Wed 11 Apr 2018 14:52:43 AEST ]]> Prediction of breast cancer risk based on profiling with common genetic variants https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:28423 Wed 11 Apr 2018 14:49:25 AEST ]]> The subclonal architecture of metastatic breast cancer: results from a prospective community-based rapid autopsy program "CASCADE" https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:29735 Wed 11 Apr 2018 14:45:58 AEST ]]> A polymorphic repeat in the IGF1 promoter influences the risk of endometrial cancer https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:26531 Wed 11 Apr 2018 14:30:11 AEST ]]> Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): A double-blind, randomised controlled trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:24206 Wed 11 Apr 2018 14:11:46 AEST ]]> Impact of deprivation on breast cancer survival among women eligible for mammographic screening in the West Midlands (UK) and New South Wales (Australia): Women diagnosed 1997-2006 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:26117 Wed 11 Apr 2018 13:45:35 AEST ]]> Are international differences in breast cancer survival between Australia and the UK present amongst both screen-detected women and non-screen-detected women?: survival estimates for women diagnosed in West Midlands and New South Wales 1997-2006 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:26118 Wed 11 Apr 2018 13:10:28 AEST ]]> Iteratively refining breast cancer intrinsic subtypes in the METABRIC dataset https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:23687 Wed 11 Apr 2018 13:07:25 AEST ]]> The potential role of miRNAs in therapy of breast and ovarian cancers associated with BRCA1 mutation https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:30577 Wed 11 Apr 2018 13:01:52 AEST ]]> Non-benzoquinone geldanamycin analogs trigger various forms of death in human breast cancer cells https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:30132 Wed 11 Apr 2018 12:53:48 AEST ]]> Participant-reported symptoms and their effect on long-term adherence in the International Breast Cancer Intervention Study I (IBIS-I) https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:29519 .05). In both treatment arms, we observed significant trends for lower adherence with increasing severity for all symptoms (P < .01) except headaches (P = .054). Conclusion: In the IBIS-I trial, experiencing predefined symptoms in the first 6 months reduced long-term adherence. Effects were similar between treatment arms, suggesting that women were attributing age-related symptoms to preventive therapy. Interventions were required to support symptom management.]]> Wed 11 Apr 2018 12:50:17 AEST ]]> The IMPAKT of breast cancer research: fundamental science and clinical medicine https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:23667 Wed 11 Apr 2018 12:36:34 AEST ]]> Basal-like breast cancer: molecular profiles, clinical features and survival outcomes https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:30824 Wed 11 Apr 2018 12:30:47 AEST ]]> Copy number variants and their role in hereditary breast cancer and hereditary colorectal cancers https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:22038 Wed 11 Apr 2018 12:26:23 AEST ]]> Physical activity and health literacy in women diagnosed with breast cancer https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:24607 Wed 11 Apr 2018 12:10:48 AEST ]]> Nerve fibers infiltrate the tumor microenvironment and are associated with nerve growth factor production and lymph node invasion in breast cancer https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:27771 In vitro, breast cancer cells were able to induce neurite outgrowth in PC12 cells, and this neurotrophic activity was partially inhibited by anti-NGF blocking antibodies. In conclusion, infiltration by nerve fibers is a feature of the tumor microenvironment that is associated with aggressiveness and involves NGF production by cancer cells. The potential participation of nerve fibers in breast cancer progression needs to be further considered.]]> Wed 11 Apr 2018 11:44:48 AEST ]]> Genetic and epigenetic changes associated with the development of lymph node metastasis in triple negative breast cancer https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:22783 Wed 11 Apr 2018 11:21:14 AEST ]]> A novel polymorphic repeat in the upstream regulatory region of the estrogen-induced gene EIG121 is not associated with the risk of developing breast or endometrial cancer https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:30240 EIG121) has been associated with breast and endometrial cancers, but its mechanism of action remains unknown. In a genome-wide search for tandem repeats, we found that EIG121 contains a short tandem repeat (STR) in its upstream regulatory region which has the potential to alter gene expression. The presence of this STR has not previously been analysed in relation to breast or endometrial cancer risk. Results: In this study, the lengths of this STR were determined by PCR, fragment analysis and sequencing using DNA from 223 breast cancer patients, 204 endometrial cancer patients and 220 healthy controls to determine if they were associated with the risk of developing breast or endometrial cancer. We found this repeat to be highly variable with the number of copies of the AG motif ranging from 27 to 72 and having a bimodal distribution. No statistically significant association was identified between the length of this STR and the risk of developing breast or endometrial cancer or age at diagnosis. Conclusions: The STR in the upstream regulatory region of EIG121 is highly polymorphic, but is not associated with the risk of developing breast or endometrial cancer in the cohorts analysed here. While this polymorphic STR in the regulatory region of EIG121 appears to have no impact on the risk of developing breast or endometrial cancer, its association with disease recurrence or overall survival remains to be determined.]]> Wed 11 Apr 2018 10:50:53 AEST ]]> Impact of CYO19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:28241 Wed 11 Apr 2018 10:43:55 AEST ]]> DNA methylation profile of triple negative breast cancer-specific genes comparing lymph node positive patients to lymph node negative patients https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:25448 Wed 11 Apr 2018 10:40:34 AEST ]]> The regulation, function and expression of Δ40p53 in breast cancer https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:27459 Wed 11 Apr 2018 10:32:51 AEST ]]> Novel genes associated with lymph node metastasis in triple negative breast cancer https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:23916 Wed 11 Apr 2018 10:32:03 AEST ]]> PRONGF/NGF and nerve infiltration in prostate and breast cancer https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:22043 Wed 11 Apr 2018 10:12:18 AEST ]]> Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:23398 Wed 11 Apr 2018 10:02:15 AEST ]]> Reevaluation of the BRCA<sub>2</sub> truncating allele c.9976A > T (p.Lys3326Ter) in a familial breast cancer context https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:22707 BRCA2, has a large number of genetic variants of unknown effect. The variant rs11571833, an A > T transversion in the final exon of the gene that leads to the creation of a stop codon 93 amino acids early (K3326*), is reported as a neutral polymorphism but there is some evidence to suggest an association with an increased risk of breast cancer. We assessed whether this variant was enriched in a cohort of breast cancer cases ascertained through familial cancer clinics compared to population-based non-cancer controls using a targeted sequencing approach. We identified the variant in 66/2634 (2.5%) cases and 33/1996 (1.65%) controls, indicating an enrichment in the breast cancer cases (p = 0.047, OR 1.53, 95% CI 1.00–2.34). This data is consistent with recent iCOGs data suggesting that this variant is not neutral with respect to breast cancer risk. rs11571833 may need to be included in SNP panels for evaluating breast cancer risk.]]> Wed 11 Apr 2018 09:55:17 AEST ]]> Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:20549 Wed 11 Apr 2018 09:50:48 AEST ]]> Cultural adaptation process of the Supportive Care Needs Survey for Mexican patients with breast cancer https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:36827 Wed 08 Jul 2020 15:05:48 AEST ]]> Evaluation of associations between genetically predicted circulating protein biomarkers and breast cancer risk https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:37129 via the integration of genomics and proteomics data. In the Breast Cancer Association Consortium (BCAC), with 122,977 cases and 105,974 controls of European descendants, we evaluated the associations of the genetically predicted concentrations of >1,400 circulating proteins with breast cancer risk. We used data from a large-scale protein quantitative trait loci (pQTL) analysis as our study instrument. Summary statistics for these pQTL variants related to breast cancer risk were obtained from the BCAC and used to estimate odds ratios (OR) for each protein using the inverse-variance weighted method. We identified 56 proteins significantly associated with breast cancer risk by instrumental analysis (false discovery rate <0.05). Of these, the concentrations of 32 were influenced by variants close to a breast cancer susceptibility locus (ABO, 9q34.2). Many of these proteins, such as insulin receptor, insulin-like growth factor receptor 1 and other membrane receptors (OR: 0.82-1.18, p values: 6.96 × 10-43.28 × 10-8), are linked to insulin resistance and estrogen receptor signaling pathways. Proteins identified at other loci include those involved in biological processes such as alcohol and lipid metabolism, proteolysis, apoptosis, immune regulation and cell motility and proliferation. Consistent associations were observed for 22 proteins in the UK Biobank data (p < 0.05). The study identifies potential novel biomarkers for breast cancer, but further investigation is needed to replicate our findings.]]> Wed 07 Apr 2021 20:21:39 AEST ]]> HER2 status predicts for upfront AI benefit: a TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:34088 Wed 06 Feb 2019 16:16:15 AEDT ]]> Treatment efficacy, adherence, and quality of life among women younger than 35 years in the International Breast Cancer Study Group TEXT and SOFT adjuvant endocrine therapy trials https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:29891 Wed 06 Feb 2019 11:42:54 AEDT ]]> Comparison of three different methods for determining cell proliferation in breast cancer cell lines https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:30103 in vitro including conventional hemocytometer counting chamber, a luminescence-based assay that utilizes the change in the metabolic activity of viable cells as a measure of the relative number of cells, and a multi-mode cell imager that measures cell number using a counting algorithm. Each method presents its own advantages and disadvantages for the measurement of cell proliferation, including time, cost and high-throughput compatibility. This protocol demonstrates that each method could accurately measure cell proliferation over time, and was sensitive to detect growth at differing cellular densities. Additionally, measurement of cell proliferation using a cell imager was able to provide further information such as morphology, confluence and allowed for a continual monitoring of cell proliferation over time. In conclusion, each method is capable of measuring cell proliferation, but the chosen method is user-dependent.]]> Wed 04 Sep 2019 10:12:09 AEST ]]> Strategies to support shared decision making in breast cancer https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:34274 Wed 04 Sep 2019 09:54:02 AEST ]]> Health literacy and physical activity in women diagnosed with breast cancer https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:31009 Wed 04 Sep 2019 09:40:16 AEST ]]> Polymorphisms in a putative enhancer at the 10q21.2 breast cancer risk locus regulate NRBF2 expression https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:28231 Wed 01 Aug 2018 14:52:20 AEST ]]> The discovery of novel biomarkers improves breast cancer intrinsic subtype prediction and reconciles the labels in the METABRIC data set https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:25143 Tue 27 Mar 2018 15:15:35 AEDT ]]> Mobile breast cancer e-support program for Chinese women with breast cancer undergoing chemotherapy (Part 2): multicenter randomized controlled trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:35186 Tue 25 Jun 2019 16:27:12 AEST ]]> Association analysis identifies 65 new breast cancer risk loci https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:33895 BRCA1, and many common, mostly non-coding variants. However, much of the genetic contribution to breast cancer risk remains unknown. Here we report the results of a genome-wide association study of breast cancer in 122,977 cases and 105,974 controls of European ancestry and 14,068 cases and 13,104 controls of East Asian ancestry. We identified 65 new loci that are associated with overall breast cancer risk at P < 5 × 10-8. The majority of credible risk single-nucleotide polymorphisms in these loci fall in distal regulatory elements, and by integrating in silico data to predict target genes in breast cells at each locus, we demonstrate a strong overlap between candidate target genes and somatic driver genes in breast tumours. We also find that heritability of breast cancer due to all single-nucleotide polymorphisms in regulatory features was 2-5-fold enriched relative to the genome-wide average, with strong enrichment for particular transcription factor binding sites. These results provide further insight into genetic susceptibility to breast cancer and will improve the use of genetic risk scores for individualized screening and prevention.]]> Tue 22 Jan 2019 14:37:29 AEDT ]]> The receptor tyrosine kinase trka is increased and targetable in HER2-positive breast cancer https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:37693 Tue 16 Mar 2021 17:30:59 AEDT ]]> Adjuvant endocrine therapy for premenopausal women: risk stratification, type and duration https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:36613 Tue 16 Jun 2020 12:01:41 AEST ]]> Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:33786 -8 with ten variants at nine new loci. At P < 0.05, we replicated associations with 10 of 11 variants previously reported in ER-negative disease or BRCA1 mutation carrier GWAS and observed consistent associations with ER-negative disease for 105 susceptibility variants identified by other studies. These 125 variants explain approximately 16% of the familial risk of this breast cancer subtype. There was high genetic correlation (0.72) between risk of ER-negative breast cancer and breast cancer risk for BRCA1 mutation carriers. These findings may lead to improved risk prediction and inform further fine-mapping and functional work to better understand the biological basis of ER-negative breast cancer.]]> Tue 15 Jan 2019 11:13:41 AEDT ]]> The association between age, comorbidities and use of radiotherapy in women with breast cancer: implications for survival https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:33410 65 years of age who received RT survived significantly longer than those who did not receive RT (aHR = 0.53, 95% CI = 0.52–0.54). However, as women aged, those with comorbidities were less likely to receive RT (adjusted p-trend by age < 0.0001). Conclusions: The development of decision-making tools to assist clinicians, and older women with breast cancer and comorbidities, are needed to facilitate personalized treatment plans regarding RT. This is particularly relevant as the population ages and the number of women with breast cancer is expected to increase in the near future.]]> Tue 03 Sep 2019 18:19:20 AEST ]]> Exploring women's experiences with a decision aid for neoadjuvant systemic therapy for operable breast cancer https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:34901 Tue 03 Sep 2019 17:58:24 AEST ]]> Can models of self-management support be adapted across cancer types? A comparison of unmet self-management needs for patients with breast or colorectal cancer https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:30002 Tue 03 Sep 2019 17:57:57 AEST ]]> Molecular patterns of cancer colonisation in lymph nodes of breast cancer patients https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:33639 Tue 03 Sep 2019 17:57:36 AEST ]]> Menopausal Hormone Therapy use and breast cancer risk by receptor subtypes: results from the New South Wales Cancer Lifestyle and EvaluAtion of Risk (CLEAR) study https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:33626 Tue 03 Sep 2019 17:56:46 AEST ]]> Adjuvant systemic treatment of premenopausal women with hormone receptor-positive early breast cancer: lights and shadows https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:34779 Thu 31 Oct 2019 16:13:17 AEDT ]]> Cross-sectional survey to inform the development of a telehealth support model: a feasibility study for women undergoing breast cancer surgery https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:36903 Thu 16 Jul 2020 12:19:42 AEST ]]> Functional identification of a novel transcript variant of INPP4B in human colon and breast cancer cells https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:31508 Sat 24 Mar 2018 08:44:17 AEDT ]]> Functional importance of PP2A regulatory subunit loss in breast cancer https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:31424 Sat 24 Mar 2018 08:43:11 AEDT ]]> Adjuvant ovarian suppression in premenopausal breast cancer https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:16697 Sat 24 Mar 2018 08:06:52 AEDT ]]> Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:21497 Sat 24 Mar 2018 08:03:39 AEDT ]]> Final 10-year results of the Breast International Group 2–98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:18606 Sat 24 Mar 2018 08:01:03 AEDT ]]> 3-Bromopyruvate induces apoptosis in breast cancer cells by downregulating Mcl-1 through the PI3K/Akt signaling pathway https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:18033 Sat 24 Mar 2018 07:56:32 AEDT ]]> Supportive care of women with breast cancer: key concerns and practical solution https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:29649 Sat 24 Mar 2018 07:41:51 AEDT ]]> Breast cancer diagnosis, patterns of care and burden of disease in Queensland, Australia (1998-2004): does being Indigenous make a difference? https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:30194 n = 110) and non-Indigenous women (n = 105), frequency matched on age and remoteness. We used Pearson’s Chi-squared analysis to compare proportions, hazard models to assess survival differences and calculated disability-adjusted life years (DALYs). Results: Indigenous women were more likely to be socially disadvantaged (43 vs. 20 %, p < 0.01) have comorbidity (42 vs. 18 % p < 0.01), and have regional spread or distant metastasis (metastasis, 51 vs. 36 %, p = 0.02) than non-Indigenous women; there was no difference in treatment patterns. More Indigenous women died in the follow-up period (p = 0.01). DALY’s were 469 and 665 per 100,000 for Indigenous and non-Indigenous women, respectively, with a larger proportion of the burden attributed to premature death among the former (63 vs. 59 %). Conclusions: Indigenous women with breast cancer received comparable treatment to their non-Indigenous counterparts. The higher proportion of DALYs related to early death in Indigenous women suggests higher fatality with breast cancer in this group. Later stage at diagnosis and higher comorbidity presence among Indigenous women reinforce the need for early detection and improved management of co-existing disease.]]> Sat 24 Mar 2018 07:41:31 AEDT ]]> Proteotranscriptomic profiling of 231-BR breast cancer cells: identification of potential biomarkers and therapeutic targets for brain metastasis https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:28878 Sat 24 Mar 2018 07:40:30 AEDT ]]> Temporal trends show improved breast cancer survival in Australia but widening urban-rural differences https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:27281 Sat 24 Mar 2018 07:40:22 AEDT ]]> Demographic, clinical, psychosocial, and environmental correlates of objectively assessed physical activity among breast cancer survivors https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:25371 Sat 24 Mar 2018 07:39:06 AEDT ]]> Development of a mobile application of Breast Cancer e-Support Program for women with breast cancer undergoing chemotherapy https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:31029 Sat 24 Mar 2018 07:34:52 AEDT ]]> Integrative review on the effectiveness of internet-based interactive programs for women with breast cancer undergoing treatment https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:31028 Sat 24 Mar 2018 07:34:52 AEDT ]]> Women's experiences of making healthcare decisions about their breast cancer: a phenomenological study https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:29555 Sat 24 Mar 2018 07:33:12 AEDT ]]> Treatment adherence and its impact on disease-free survival in the breast international group 1-98 trial of tamoxifen and letrozole, alone and in sequence https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:30333 Sat 24 Mar 2018 07:31:47 AEDT ]]> Low-dose oral cyclophosphamide and methotrexate maintenance for hormone receptor-negative early breast cancer: International Breast Cancer Study Group Trial 22-00 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:29018 P = .14) and in triple-negative (TN) disease (n = 814; HR, 0.80; 95% CI, 0.60 to 1.06). Patients with TN, node-positive disease had a nonstatistically significant reduced HR (n = 340; HR, 0.72; 95% CI, 0.49 to 1.05). Seventy-one (13%) of 542 patients assigned to CM maintenance did not start CM. Of 473 patients who received at least one CM maintenance dose (including two patients assigned to no CM), 64 (14%) experienced a grade 3 or 4 treatment-related adverse event; elevated serum transaminases was the most frequently reported (7%), followed by leukopenia (2%). Conclusion: CM maintenance did not produce a significant reduction in DFS events in hormone receptor-negative early breast cancer. The trend toward benefit observed in the TN, node-positive subgroup supports additional exploration of this strategy in the TN, higher-risk population.]]> Sat 24 Mar 2018 07:31:09 AEDT ]]> Albumin hybrid nanoparticles loaded with tyrosine kinase A inhibitor GNF-5837 for targeted inhibition of breast cancer cell growth and invasion https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:25752 Sat 24 Mar 2018 07:30:53 AEDT ]]> Utilisation of MR spectroscopy and diffusion weighted imaging in predicting and monitoring of breast cancer response to chemotherapy https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:25640 Sat 24 Mar 2018 07:28:09 AEDT ]]> Main outcomes of the Move More for Life Trial: a randomised controlled trial examining the effects of tailored-print and targeted-print materials for promoting physical activity among post-treatment breast cancer survivors https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:25666 Sat 24 Mar 2018 07:28:04 AEDT ]]> Consensus on breast cancer cell lines classification for an effective and efficient clinical decision-making https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:26008 Sat 24 Mar 2018 07:24:31 AEDT ]]> Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:27579 Sat 24 Mar 2018 07:23:42 AEDT ]]> The presence of the intron 3 16 bp duplication polymorphism of p53 (rs17878362) in breast cancer is associated with a low ∆40p53:p53 ratio and better outcome https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:24332 Sat 24 Mar 2018 07:16:38 AEDT ]]> Estrogen receptor expression in 21-gene recurrence score predicts increased late recurrence for estrogen-positive/HER2-negative breast cancer https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:22830 interaction = 0.004). Estrogen receptor transcript levels showed inverse prediction across the time windows: HR, 0.88 (0.73–1.07) and 1.19 (0.99–1.43), respectively (Pinteraction = 0.03). Similar time-, module-, and estrogen-dependent relationships were seen for distant recurrence. Conclusions: Patients with tumors with high estrogen receptor transcript levels benefit most from 5 years' endocrine therapy but show increased recurrence rates after 5 years and may benefit from extended therapy. Improved prognostic profiles may be created by considering period of treatment and follow-up time.]]> Sat 24 Mar 2018 07:16:07 AEDT ]]> Genes associated with histopathologic features of triple negative breast tumors predict molecular subtypes https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:24832 Sat 24 Mar 2018 07:15:11 AEDT ]]> Panel testing for familial breast cancer: calibrating the tension between research and clinical care https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:24890 Sat 24 Mar 2018 07:14:53 AEDT ]]> Annual hazard rates of recurrence for breast cancer during 24 years of follow-up: results from the International Breast Cancer Study Group Trials I to V https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:24426 Sat 24 Mar 2018 07:14:26 AEDT ]]> Exploring decision-making about neo-adjuvant chemotherapy for breast cancer (letter) https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:24782 The Breast Journal.]]> Sat 24 Mar 2018 07:14:06 AEDT ]]> Adjuvant ovarian function suppression and cognitive function in women with breast cancer https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:24211 Sat 24 Mar 2018 07:12:41 AEDT ]]> Reevaluation of RINT1 as a breast cancer predisposition gene https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:23843 0.999) or in the number of variants predicted to be pathogenic by various in silico tools (Condel, Polyphen2, SIFT, and CADD) in the cases compared to the controls. In addition, there was no difference in the incidence of classic Lynch syndrome cancers in RINT1 rare variant-carrying families compared to RINT1 wild-type families. This study had 90 % power to detect an odds ratio of at least 2.06, and the results do not provide any support for RINT1 being a moderate-penetrance breast cancer susceptibility gene, although larger studies will be required to exclude more modest effects. This study emphasizes the need for caution before designating a cancer predisposition role for any gene based on very rare truncating variants and in silico-predicted missense variants.]]> Sat 24 Mar 2018 07:12:12 AEDT ]]> The functional role of PPP2R2A in luminal breast cancer https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:36157 Mon 26 Oct 2020 12:11:15 AEDT ]]> p-STAT3 in luminal breast cancer: Integrated RNA-protein pooled analysis and results from the BIG 2-98 phase III trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:32265 Mon 23 Sep 2019 13:56:46 AEST ]]> Evolutionary wavelet neural network ensembles for breast cancer and Parkinson's disease prediction https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:32038 Mon 23 Sep 2019 13:42:04 AEST ]]> Early participant reported symptoms as predictors of adherence to anastrozole in the International Breast Cancer Intervention Studies II https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:32258 Mon 23 Sep 2019 13:24:38 AEST ]]> A mobile application of a breast cancer e-support program for Chinese women with breast cancer undergoing chemotherapy https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:33127 Mon 23 Sep 2019 12:39:30 AEST ]]> Mobile breast cancer e-support program for Chinese women with breast cancer undergoing chemotherapy (Part 1): qualitative study of women's perceptions https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:32034 Mon 23 Sep 2019 12:04:09 AEST ]]> ProNGF, NGF and their receptors in tumour innervation and progression: a study in breast and thyroid cancers https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:31979 Mon 23 Sep 2019 11:59:37 AEST ]]> Breast cancer intrinsic subtypes: a critical conception in bioinformatics https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:30639 Mon 23 Sep 2019 11:53:06 AEST ]]> Participant-reported symptoms and their effect on long-term adherence in the International Breast Cancer Intervention Study I (IBIS I) https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:32264 .05). In both treatment arms, we observed significant trends for lower adherence with increasing severity for all symptoms (P < .01) except headaches (P = .054). Conclusion: In the IBIS-I trial, experiencing predefined symptoms in the first 6 months reduced long-term adherence. Effects were similar between treatment arms, suggesting that women were attributing age-related symptoms to preventive therapy. Interventions were required to support symptom management.]]> Mon 23 Sep 2019 11:46:30 AEST ]]> Mammographic (breast) density as a potential biomarker for endocrine trial treatment efficacy in breast cancer prevention https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:32394 Mon 23 Sep 2019 11:45:21 AEST ]]> Women's experiences with deciding on neoadjuvant systemic therapy for operable breast cancer: a qualitative study https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:32035 Mon 23 Sep 2019 11:18:09 AEST ]]> When do patient reported quality of life indicators become prognostic in breast cancer? https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:32263 Mon 23 Sep 2019 10:48:43 AEST ]]> Multifunctional nanomedicines based on albumin for targeted breast cancer therapy https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:27891 Mon 23 Sep 2019 10:12:42 AEST ]]> Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:24831 -8) with oestrogen receptor (ER)-negative breast cancer and BRCA1-associated breast cancer risk. In this study, to identify new ER-negative susceptibility loci, we performed a meta-analysis of 11 genome-wide association studies (GWAS) consisting of 4,939 ER-negative cases and 14,352 controls, combined with 7,333 ER-negative cases and 42,468 controls and 15,252 BRCA1 mutation carriers genotyped on the iCOGS array. We identify four previously unidentified loci including two loci at 13q22 near KLF5, a 2p23.2 locus near WDR43 and a 2q33 locus near PPIL3 that display genome-wide significant associations with ER-negative breast cancer. In addition, 19 known breast cancer risk loci have genome-wide significant associations and 40 had moderate associations (P<0.05) with ER-negative disease. Using functional and eQTL studies we implicate TRMT61B and WDR43 at 2p23.2 and PPIL3 at 2q33 in ER-negative breast cancer aetiology. All ER-negative loci combined account for ~11% of familial relative risk for ER-negative disease and may contribute to improved ER-negative and BRCA1 breast cancer risk prediction.]]> Mon 11 Mar 2019 12:13:11 AEDT ]]> Tumor-infiltrating lymphocytes and prognosis: a poled individual patient analysis of early-stage triple-negative breast cancers https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:34339 Mon 03 Feb 2020 11:52:07 AEDT ]]> Gelatin-albumin hybrid nanoparticles as matrix metalloproteinases-degradable delivery systems for breast cancer therapy https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:34716 Fri 26 Apr 2019 15:52:16 AEST ]]> The preventable burden of breast cancers for premenopausal and postmenopausal women in Australia: A pooled cohort study https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:37400 n = 214,536) to national cancer and death registries, and estimated the strength of the associations between behaviours causally related to cancer incidence and death using adjusted proportional hazards models. We estimated exposure prevalence from representative health surveys. We combined these estimates to calculate Population Attributable Fractions (PAFs) with 95% confidence intervals (CIs), and compared PAFs for population subgroups. During the first 10 years follow‐up, there were 640 incident breast cancers for premenopausal women, 2,632 for postmenopausal women, and 8,761 deaths from any cause. Of future breast cancers for premenopausal women, any regular alcohol consumption explains 12.6% (CI = 4.3–20.2%), current use of oral contraceptives for ≥5 years 7.1% (CI = 0.3–13.5%), and these factors combined 18.8% (CI = 9.1–27.4%). Of future breast cancers for postmenopausal women, overweight or obesity (BMI ≥25 kg/m2) explains 12.8% (CI = 7.8–17.5%), current use of menopausal hormone therapy (MHT) 6.9% (CI = 4.8–8.9%), any regular alcohol consumption 6.6% (CI = 1.5–11.4%), and these factors combined 24.2% (CI = 17.6–30.3%). The MHT‐related postmenopausal breast cancer burden varied by body fatness, alcohol consumption and socio‐economic status, the body fatness‐related postmenopausal breast cancer burden by alcohol consumption and educational attainment, and the alcohol‐related postmenopausal breast cancer burden by breast feeding history. Our results provide evidence to support targeted and population‐level cancer control activities.]]> Fri 06 Nov 2020 17:34:03 AEDT ]]> The function of Δ40p53 in breast cancer https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:36560 Fri 05 Jun 2020 20:10:17 AEST ]]>